Form 4: Director Waddill Sells PTGX Shares After Option Exercise

Protagonist Therapeutics Director William D. Waddill exercised stock options and sold 20,000 common shares for a significant gain in a pre-planned transaction.

Summary

• William D. Waddill, a Director of Protagonist Therapeutics, Inc. (PTGX), engaged in a transaction involving the exercise of stock options and the subsequent sale of common stock.
• The transaction, dated February 6, 2026, was conducted pursuant to a Rule 10b5-1(c) pre-planned trading arrangement.
• Waddill exercised 20,000 fully vested stock options at an exercise price of $8.31 per share.
• Concurrently, 20,000 shares of common stock were sold at a weighted average price of $83.68 per share, with individual sales ranging from $83.65 to $83.87.
• Following these transactions, Waddill's direct beneficial ownership of Protagonist Therapeutics common stock is 7,825 shares, and no derivative securities are beneficially owned.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves insider selling, the transaction is pre-planned under Rule 10b5-1(c) and represents a routine exercise of vested options for liquidity, which is common for executives. The significant gain realized by the director is a positive for the individual.

Positives

• The reporting person realized a significant gain from the exercise of options and subsequent sale of shares, with an implied gross profit of approximately $1,507,400 from this specific transaction.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned disposition rather than a reaction to immediate market conditions.

Negatives

• The sale of 20,000 common shares by a director could be perceived by some investors as a negative signal, although it was part of a pre-planned arrangement.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving the exercise of vested stock options and subsequent sale of shares under a Rule 10b5-1 plan, are common occurrences in the biotechnology and pharmaceutical industries. These transactions often represent routine liquidity events for executives managing their equity compensation rather than a direct signal about the company's immediate prospects.

Stakeholder Impact

• Shareholders may interpret the insider sale differently; some may view it as a routine liquidity event, while others might perceive it as a lack of confidence, despite the 10b5-1 plan.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, Insider Trading, Form 4, Stock Options, Share Sale, William D. Waddill, 10b5-1 Plan